A Fast-Acting Dupixent? Dr. Barry Quart, CEO, Connect Biopharma

episode

BioTech Nation ... with Dr. Moira Gunn not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

America at the Crossroads_ 2026 and Beyond (1) 3 min · 22 Sep 2026 · Conspiracy Theories Exploring The Unseen

Trust in America, Part 2_ The Tribalization of Truth 3 min · 22 Sep 2026 · Conspiracy Theories Exploring The Unseen

The Trust Deficit_ Why We Stopped Believing Part 1 2 min · 22 Sep 2026 · Conspiracy Theories Exploring The Unseen

The Retirement Paradox_ Are We Ready_ (Part 2) 2 min · 22 Sep 2026 · Conspiracy Theories Exploring The Unseen

NPR News: 09-22-2026 9AM EDT 5 min · 22 Sep 2026 · NPR News Now

The Retirement Reality Check_ Part 1 3 min · 22 Sep 2026 · Conspiracy Theories Exploring The Unseen

Report any issue

Source

Recorded11 Jan 2026

Publisherfeeds.transistor.fm ↗

Handlerec:15253118

Show notes

On this episode of BioTech Nation, Moira speaks with Dr. Barry Quart, CEO of Connect Biopharma, about a new fast-acting treatment for inflammatory conditions like Asthma, COPD, and Eczema. Often, these conditions can be managed with anti-inflammatory therapeutics like Dupixent, but even then, sudden and painful flare-ups can occur. We take a closer look at a new anti-inflammatory in late-stage development which starts working quickly, much needed when those flare-ups develop.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in